<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">The current inactivated influenza vaccine formulation does not boost T cell response (Koutsakos 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR52">2018</xref>). Nevertheless cytotoxic CD8
 <sup>+</sup> T cells specific to the conserved viral epitopes have been evidenced to provide cross-protection across IAV, IBV and ICV (McMichael 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR72">1983</xref>; Greenbaum 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR38">2009</xref>; Gras 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR36">2010</xref>; Sridhar 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR90">2013</xref>; Quinones-Parra 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR84">2014</xref>; Hayward 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR40">2015</xref>; Wang 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR103">2015</xref>, 
 <xref ref-type="bibr" rid="CR104">2018</xref>; Koutsakos 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR53">2019</xref>). Moreover, pre-existing T cell responses have been demonstrated to correlate with protection from influenza disease in humans by epidemiological studies (Epstein 
 <xref ref-type="bibr" rid="CR31">2006</xref>; Hayward 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR40">2015</xref>). The antigenic origin of these broadly cross-reactive epitopes is therefore of great interest in the development of CD8
 <sup>+</sup> T cell-based universal influenza vaccines. It is believed that CD8
 <sup>+</sup> T cell cross-reactivity is provided by the peptides derived from internal influenza proteins, mainly but not limited to nucleoprotein (NP) and matrix protein 1 (M1) (Fig.Â 
 <xref rid="Fig2" ref-type="fig">2</xref>B) (Koutsakos 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR53">2019</xref>).
</p>
